Multidrug resistance 1 gene (P-glycoprotein 170): An important determinant in gastrointestinal disease?

Gut

Volumn 52, Issue 5, 2003, Pages 759-766

  Ho, G T ^a   Moodie, F M ^a   Satsangi, J ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CORTICOSTERONE; CYCLOSPORIN; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DIGOXIN; DOMPERIDONE; DOXORUBICIN; ERYTHROMYCIN; ETOPOSIDE; GLYCOPROTEIN P; HYDROCORTISONE; INDINAVIR; LOPERAMIDE; METHOTREXATE; MEVINOLIN; NELFINAVIR; PACLITAXEL; PRAZOSIN; PROGESTERONE; QUINIDINE; RIFAMPICIN; RITONAVIR; TACROLIMUS; TERFENADINE; VINCA ALKALOID;

COLORECTAL CARCINOMA; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG BIOAVAILABILITY; DRUG FECES LEVEL; GASTROINTESTINAL DISEASE; GENE OVEREXPRESSION; GENETIC CODE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HOMEOSTASIS; HOST PATHOGEN INTERACTION; HUMAN; INTESTINE EPITHELIUM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSPORT KINETICS;

ADRENAL CORTEX HORMONES; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CROHN DISEASE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, MULTIPLE; GASTROINTESTINAL DISEASES; GENE EXPRESSION REGULATION; GENES, MDR; HUMANS; MULTIGENE FAMILY; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS;

EID: 0037624566     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.5.759     Document Type: Review

References (87)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62.
2. Hsu SI, Lothstein L, Horwitz SB. Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. Evidence that distinct P- glycoprotein precursors are encoded by unique mdr genes. J Biol Chem 1989;264:12053-62.
3. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381-9.
4. Ueda K, Clark DP, Chen CJ, et al. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 1987;262:505-8.
5. Fardel O, Payen L, Courtois A, et al. Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology 2001;167:37-46.
6. Smit JJ, Schinkel AH, Oude ER, et al. Homozygous disruption of the murine mdr2 P- glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993;75:451-62.
7. Deleuze JF, Jacquemin E, Dubuisson C, et al. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996;23:904-8.
8. Jacquemin E. Progressive familial intrahepatic cholestasis. Genetic basis and treatment. Clin Liver Dis 2000;4:753-63.
9. Nagata K, Nishitani M, Matsuo M, et al. Nonequivalent nucleotide trapping in the two nucleotide binding folds of the human multidrug resistance protein MRP1. J Blot Chem 2000;275:17626-30.
10. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug- resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735-8.
11. Wijnholds J, Evers R, van Leusden MR, et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 1997;3:1275-9.
12. Rao VV, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood- cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 1999;96:3900-5.
13. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P- glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989;86:695-8.
14. Zhao JY, Ikeguchi M, Eckersberg T, et al. Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology 1993;133:521-8.
15. Klimecki WT, Futscher BW, Grogan TM, et al. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994;83:2451-8.
16. Chianale J, Vollrath V, Wielandt AM, et al. Differences between nuclear run-off and mRNA levels for multidrug resistance gene expression in the cephalocaudal axis of the mouse intestine. Biochim Biophys Acta 1995;1264:369-76.
17. Fricker G, Drewe J, Huwyler J, et al. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 1996;118:1841-7.
18. Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987;84:265-9.
19. Yumoto R, Murakami T, Sanemasa M, et al. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone. Drug Metab Dispos 2001;29:145-51.
20. Trezise AE, Romano PR, Gill DR, et al. The multidrug resistance and cystic fibrosis genes have complementary patterns epithelial expression. EMBO J 1992;11:4291-303.
21. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996;14:199-202.
22. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998;161:5733-44.
23. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 1997;94:4028-33.
24. Shomer NH, Dangler CA, Marini RP, et al. Helicobacter bilis/Helicobacter rodentium co-infection associated with diarrhea in a colony of scid mice. Lab Anim Sci 1998;48:455-9.
25. Cahill RJ, Foltz CJ, Fox JG, et al. Inflammatory bowel disease: an immunity, mediated condition triggered by bacterial infection with Helicobacter hepaticus. Infect Immun 1997;65:3126-31.
26. Burich A, Hershberg R, Waggie K, et al. Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. Am J Physiol Gastrointest Liver Physiol 2001;281:G764-78.
27. Cahill RJ, Foltz CJ, Fox JG, et al. Inflammatory bowel disease: an immunity- mediated condition triggered by bacterial infection with Helicobacter hepaticus. Infect Immun 1997;65:3126-31.
28. Gewirtz AT, Navas TA, Lyons S, et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001;167:1882-5.
29. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000;289:1560-3.
30. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997;94:2031-5.
31. Mayer U, Wagenaar E, Beijnen JH, et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol 1996;119:1038-44.
32. Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 2001;50(suppl 1):S3-11.
33. Labialle S, Gayet L, Marthinet E, et al. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 2002;64:943-8.
34. Shapiro AB, Fox K, Lam P, et al. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 1999;259:841-50.
35. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147-53.
36. Asghar A, Gorski JC, Haehner-Daniels B, et al. Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos 2002;30:20-6.
37. Westphal K, Weinbrenner A, Zschiesche M, et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 2000;68:345-55.
38. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001;276:14581-7.
39. Salphati L, Benet LZ. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol 1998;55:387-95.
40. Lin JH, Chiba M, Chen IW, et al. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A (correction of P-450 A) and p-glycoprotein induction. Drug Metab Dispos 1999;27:1187-93.
41. Demeule M, Jodoin J, Beaulieu E, et al. Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett 1999;442:208-14.
42. Murakami T, Yumoto R, Nagai J, et al. Factors affecting the expression and function of P-glycoprotein in rats: drug treatments and diseased states. Pharmazie 2002;57:102-7.
43. Mickley LA, Spengler BA, Knutsen TA, et al. Gene rearrangement: a novel mechanism for MDR-1 gene activation. J Clin Invest 1997;99:1947-57.
44. Van Den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ, et al. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 2001;97:3605-11.
45. van der Kolk DM, de Vries EG, Noordhoek L, et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 2001;15:1544-53.
46. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69:169-74.
47. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P- glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-8.
48. Drescher S, Schaeffeler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-34.
49. Tang K, Ngoi SM, Gwee PC, et al. Distinct haplotype profiles and strong rinkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002;12:437-50.
50. Kimchi-Sarfaty C, Gribor JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 2002;62:1-6.
51. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-99.
52. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV- 1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359:30-6.
53. Hitzl M, Drescher S, van der Kuip H, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001;11:293-8.
54. Nakamura T, Sakaeda T, Horinouchi M, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic ocid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002;71:297-303.
55. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000;118:279-88.
56. Yacyshyn B, Maksymowych W, Bowen-Yacyshyn MB. Differences in P-glycoprotein- 170 expression and activity between Crohn's disease and ulcerative colitis. Hum Immunol 1999;60:677-87.
57. Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992;267:24248-52.
58. Farrell RJ, Menconi MJ, Keates AC, et al. P-Glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes. Ailment Pharmacol Ther 2002;16:1021-31.
59. Montano E, Schmitz M, Blaser K, et al. P-glycoprotein expression in circulating blood leukocytes of patients with steroid-resistant asthma. J Investig Allergol Clin Immunol 1996;6:14-21.
60. Maillefert JF, Maynadie M, Tebib JG, et al. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol 1996;35:430-5.
61. Ludescher C, Pall G, Irschick EU, et al. Differential activity of P-glycoprotein in normal blood lymphocyte subsets. Br J Haematol 1998;101:722-7.
62. Potocnik U, Ravnik-Glavac M, Golouh R, et al. Naturally occurring mutations and Functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers. J Med Genet 2002;39:340-6.
63. Kornek G, Schenk T, Raderer M, et al. Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours. Br J Cancer 1995;71:182-5.
64. Scheithauer W, Schenk T, Czejka M. Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil. Br J Cancer 1993;68:8-9.
65. Czejka MJ, Schenk T, Scheithauer W. The combination of epirubicin with d- verapamil and/or tamoxifen in cell cultures. Pharmazie 1993;48:148-9.
66. Van Den Heuvel-Eibrink MM, Sonneveld P, Pieters R. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 2000;38:94-110.
67. Chan HS, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-14.
68. Weinstein RS, Jakate SM, Dominguez JM, et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human cobn carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991;51:2720-6.
69. Sinicrope FA, Hart J, Brasitus TA, et al. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer 1994;74:2908-17.
70. Ando Y, Tsuchiya A, Oki S, et al. Flow cytometric DNA analysis of malignant potential in colorectal cancer. Gan To Kagaku Ryoho 1996;23(suppl 2):112-7.
71. Pirker R, Wallner J, Gsur A, et al. MDR1 gene expression in primary colorectal carcinomas. Br J Cancer 1993;68:691-4.
72. Wallner J, Depisch D, Gsur A, et al. MDR1 gene expression and its clinical relevance in primary gastric carcinomas. Cancer 1993;71:667-71.
73. Yamada T, Takaoka AS, Naishiro Y, et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 2000;60:4761-6.
74. Munemitsu S, Albert J, Souza B, et al. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci U S A 1995;92:3046-50.
75. He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45.
76. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
77. Ougolkov AV, Yamashita K, Mai M, et al. Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 2002;122:60-71.
78. Davies G, Jiang WG, Mason MD. Matrilysin mediates extracellular cleavage of E- cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. Clin Cancer Res 2001;7:3289-97.
79. Brabletz T, Jung A, Dag S, et al. beta-Catenin induces invasive growth by activating matrix metalloproteinases in colorectal carcinoma. Verh Dtsch Ges Pathol 2000;84:175-81.
80. Arber N, Hibshoosh H, Moss SF, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110:669-74.
81. Yamada T, Takaoka AS, Naishiro Y, et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 2000;60:4761-6.
82. Smyth MJ, Johnstone RW, Cretney E, et al. Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice. J Immunol 1999;163:1350-3.
83. Bush JA, Li G. Regulation of the Mdr1 isoforms in a p53-deficient mouse model. Carcinogenesis 2002;23:1603-7.
84. Sampath J, Sun D, Kidd VJ, et al. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 2001;276:39359-67.
85. Nguyen KT, Liu B, Ueda K, et al. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res 1994;6:71-7.
86. Chin KV, Ueda K, Pastan I, et al. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992;255:459-62.
87. Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002;123:106-11.